Medtronic  has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office rejected in its entirety Axonics' attempt to invalidate a key Medtronic patent. "Medtronic is pleased with the PTAB's decision to uphold the most important of the patents challenged," ...

Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office rejected in its entirety Axonics' attempt to invalidate a key Medtronic patent.

"Medtronic is pleased with the PTAB's decision to uphold the most important of the patents challenged," said Brooke Story , vice president and general manager of Medtronic's Pelvic Health & Gastric Therapies business, which is part of the Restorative Therapies Group. "Innovation is vital to our business and we will vigorously defend our IP Portfolio in this case."

Medtronic filed suit against Axonics in November 2019 , asserting claims for infringement of seven patents. In response, Axonics filed Inter Partes Review (IPR) on all seven patents. However, the PTAB has now rejected without hearing the challenge to Medtronic's U.S. Patent No. 9,463,324 ('324 patent) and found that Axonics' arguments lack merit. The '324 patent protects key technology related to implant recharging and temperature control and is central to the infringement case pending against Axonics. In rejecting Axonics' arguments, the PTAB found there was no reasonable likelihood that any claims of the '324 patent are invalid. That decision by the PTAB is final and not appealable.

Over the last week, the PTAB has also decided to institute full IPR proceedings related to the six additional patents at issue. In those IPR proceedings, the PTAB will hear testimony and argument from both sides.

"Contrary to Axonics' assertions, the PTAB has not made any final determination that any of Medtronic's patent claims are invalid," said Story. "The full IPR process will begin now, and the PTAB will issue a decision within the next 12 months."

Medtronic has the world's smallest rechargeable bladder/bowel control system and the fastest battery recharge available and is the only company that offers patients the choice of a rechargeable or recharge-free sacral neuromodulation device. With 25-years' experience of innovation, investment and pioneering therapy, Medtronic is the only company with five-year data across four indications demonstrating the safety and efficacy of its sacral neuromodulation systems.

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:




Katie Genereux

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-514-0162

+1-763-505-4626

Cision View original content to download multimedia: http://www.prnewswire.com/news-releases/medtronic-gets-affirmation-of-key-sacral-neuromodulation-patent-301138320.html

SOURCE Medtronic plc

News Provided by PR Newswire via QuoteMedia

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

Leveljump Healthcare Corp. Announces $3.2 Million Term Loan Commitment from TD Canada Trust

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that it has secured a term loan commitment from TD Canada Trust for $3.2 million for the purpose of closing the Company's previously announced acquisition of three Ontario Diagnostic Imaging Clinics (Press release September 28, 2021).

Combined with the Company's cash on hand, the term loan will allow the Company to close the Ontario Diagnostic Imaging Clinics acquisition.

Keep reading... Show less
Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

Leveljump Healthcare Corp. Announces 13.1% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 13.1% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,244,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

HealthTab to Offer Abbott's i-STAT Alinity, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce the signing of a non-exclusive, pilot supplier distribution agreement in Canada between HealthTab™ Inc., a wholly owned subsidiary, and Abbott, the global healthcare company, with respect to the handheld blood chemistry analyzer, i-STAT Alinity.

The agreement allows HealthTab to distribute Abbott's point-of-care i-STAT Alinity and its associated tests for creatinine in Canadian pharmacies to better support patients with important information about their renal function.

Keep reading... Show less

Medtronic Reports Second Quarter Fiscal 2022 Financial Results

- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021 .

Keep reading... Show less

Top News

Related News